Clostridium difficile infection (CDI) is one of the leading causes of hospital-acquired infections in recent times. Hematopoietic stem cell transplantation (HSCT) confers increased risk for CDI because of prolonged hospital stay, immunosuppression, the need to use broad-spectrum antibiotics and a complex interplay of preparative regimen and GvHD-induced gut mucosal damage. Our study evaluated risk factors (RF) for recurrent CDI in HSCT recipients given the ubiquity of traditional RF for CDI in this population. Of the 499 allogeneic HSCT recipients transplanted between 2005 and 2012, 61 (12%) developed CDI within 6 months before transplant or 2 years after transplant and were included in the analysis. Recurrent CDI occurred in 20 (33%) patients. One year incidence of CDI recurrence was 31%. Multivariable analyses identified the number of antecedent antibiotics other than those used to treat CDI as the only significant RF for recurrence (hazard ratio 1.96, 95% confidence interval 1.09-3.52, P = 0.025). Most recurrences occurred within 6 months of the first CDI, and the recurrence of CDI was associated with a trend for increased risk of mortality. This prompts the need for further investigation into secondary prophylaxis to prevent recurrent CDI. 
INTRODUCTION
Clostridium difficile (C. diff) infection (CDI) is one of the leading causes of hospital-acquired infections in recent times. Allogeneic hematopoietic stem cell transplantation (HSCT) confers increased risk for CDI because of prolonged hospital stay, immunosuppression, the need to use broad-spectrum antibiotics and a complex interplay of chemo-preparative regimen and GvHD-induced gut mucosal damage. The incidence of CDI following autologous and allogeneic HSCT ranges from 5 to 20% [1] [2] [3] [4] [5] [6] [7] [8] and recurrence rate has been~20%; 1 consistent with the general population. There are numerous studies describing the epidemiology and risk factors (RFs) of recurrent CDI in the general population, namely receipt of antibiotics, age 460 years, length of hospital stay and concomitant receipt of antacid medications. [9] [10] [11] [12] Allogeneic HSCT recipients are a unique patient population, given the ubiquity of traditional risk factors and gut involvement with GvHD, with three studies showing an increased risk of CDI in patients with GvHD, 1, 3, 7 and there is a need to understand the risk of recurrence in this highly vulnerable group of immunosuppressed patients. Identifying these RFs will enable us to establish preventive measures for CDI by modifying our infection prevention and antibiotic utilization policies.
PATIENTS AND METHODS
We conducted a single institution retrospective analysis of allogeneic HSCT recipients who had CDI in the period within 6 months before transplant and up to 2 years after transplant to identify the RF for recurrent CDI. The bone marrow transplant database at Cleveland Clinic was used to identify patients. Between 2005 and 2012, 499 patients underwent allogeneic HSCT at our institution. Of these, 61 (12%) had CDI in the period within 6 months before transplant and up to 2 years after transplant and 20 (33%) of the 61 patients had recurrent CDI. CDI was confirmed by electronic medical record review. Additional data not available in the transplant database were obtained by reviewing electronic medical records by a single reviewer. At our institution, C. diff was detected in the stool by enzyme immunoassay for toxin A and B before 2010 and by PCR for toxin A and B since 2010. This study was approved by the institutional review board at Cleveland Clinic.
Definitions
Infectious Disease Society of America defined CDI as presence of symptoms, usually diarrhea with either a stool test positive for C. diff toxins or colonoscopic or histopathologic evidence of pseudomembranous colitis. 13 Diarrhea is defined as three or more unformed stools within 24 h or fewer consecutive hours. Recurrent CDI is defined as any CDI that occurs after the first appropriately treated episode with 10-14 days of either oral metronidazole or vancomycin. Further subclassification of recurrences as relapse (defined as any CDI occurring within 2-8 weeks from first infection) or reinfection (defined as any CDI 48 weeks from first infection) was done based on Centers for Disease Control and Prevention (CDC) guidelines. 14 Antecedent antibiotic use was defined as use of antibiotic (excluding vancomycin and metronidazole) within 8 weeks before any episode of CDI. GvHD of the GI tract was graded according to the standard definition by International Bone Marrow Transplant Registry. 15 Grade 3-4 acute GI GvHD was classified as severe GvHD.
Statistical analysis
Patient characteristics are described as frequency counts and percentages, or as the median and range. CDI recurrence was calculated from the date of the initial CDI until the date of recurrence or last follow-up; death without CDI recurrence was analyzed as a competing risk. CDI recurrence was estimated using the cumulative incidence method. Competing risk regression was done using the method of Fine and Gray. 16 Eleven variables were assessed as risk factors for recurrent CDI: age, gender, race, number of prior chemotherapy regimens, HSCT comorbidity index, donor relationship, type of transplant, hematopoietic cell source, use of proton pump inhibitors, number of non-C. diff antibiotics and GvHD. Recurrent CDI after the initial CDI was analyzed as a time-varying covariate in a Cox proportional hazards model to determine its effect on survival after the initial CDI. Fine and Gray and Cox analyses are presented as hazard ratios and 95% confidence intervals. Competing risk regression was done with the cmprsk package in R (Linux version 3.0.0, http://www.r-project.org/); all other analyses were done with SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). All the statistical tests were two-sided, and Po0.05 was used to indicate statistical significance.
RESULTS

Patient characteristics
We report the data on 61 of 499 patients (12%) who developed CDI in the period within 6 months before transplant and up to 2 years after transplant (Table 1) . Thirty-five patients (57%) developed first CDI within 100 days of HSCT. Our study population had a median age of 49 (range 2-73) years; 52% were male. Acute myeloid leukemia was the most common underlying hematologic malignancy (41%). Majority of the patients received a myeloablative preparative regimen (74%), more commonly from unrelated donors (63%), with bone marrow being the most common graft source (55%). Fifty-nine percent developed acute GvHD. The patients were followed for a median of 27 (range 8-89) months after the first episode of CDI.
Recurrent CDI occurred in 20 patients (33%). All recurrences occurred after the allogeneic HSCT and were reinfections based on the clinical criteria established by CDC. The 1-year incidence of recurrent CDI was 31%. Eighty-five percent (17/20) of recurrences occurred within the first 6 months of the first CDI ( Figure 1 ).
Risk factors for recurrent CDI
The number of antecedent antibiotics, excluding C. diff treatment, was the only significant RF associated with recurrent CDI (hazard ratio = 1.96, 95% confidence interval = 1.09-3.52, P = 0.025) in both univariable and multivariable analyses (Table 2; Figure 2 ). The risk of recurrence increased almost twofold with every single increase in the number of antibiotics. All but one patient received at least one antibiotic before CDI; 77% received a beta-lactam antibiotic and 38% received fluoroquinolones. All but one of our patients received at least one antecedent antibiotic, 39.3% received two antibiotics and 11.5% patients received three antibiotics. We did not detect statistically significant association between GvHD and recurrent CDI.
Outcomes of CDI Of the 61 patients with CDI, 30 patients (49%) died during followup: 10 of these patients had recurrent CDI; and toxic megacolon owing to CDI was the cause of death in only one patient with recurrent CDI. Cox proportional hazards analysis suggested that recurrent CDI was associated with a trend for increased risk of mortality (hazard ratio = 2.36, confidence interval = 0.98-5.71, P = 0.06).
DISCUSSION
In our study 12% of the allogeneic HSCT recipients developed CDI and there was a higher 1-year incidence of CDI recurrence of 31% compared with other studies. We included only allogeneic HSCT recipients in our study given the differences in transplant-related events and risk factors between autologous and allogeneic stem cell transplantation. The high rate of recurrence prompts us to have a high suspicion for C. diff infection in this patient population, where other important causes of acute diarrhea, for example, CMV infection and GvHD are entertained. reported 39 cases and two recurrences of CDI in their cohort of 216 allogeneic HSCT recipients. Huang et al. 17 studied the RF for recurrent CDI in both allogeneic and autologous HSCT recipients and identified 14 patients with recurrent CDI in the allogeneic group. Our study is one of the largest, to our knowledge, among allogeneic transplant recipients (61 patients with CDI and 20 patients with recurrent CDI) with median follow-up of 42 years to assess the RF for recurrence. We included patients who had CDI 6 months before HSCT as there has been an increase in community-acquired CDI lately, 18 and a proportion of patients are colonized with C. diff before hospitalization for HSCT.
The high 1-year recurrence incidence of 31% in our study compared with 20% in hospitalized general patient population could be explained by the inherently complex nature of allogeneic HSCT and longer duration of follow-up in our study. Abbreviations: BM = bone marrow; CI = confidence interval; GI = gastrointestinal; HCT = hematopietic cell transplant; HR = hazard ratio; MA = myeloablative; PSC = peripheral stem cell; RIC = reduced intensity conditioning; UCB = umbilical cord blood. a Significant risk factor in multivariate analyses. Figure 2 . Depicts non-C. diff antibiotics as a significant risk factor for recurrence. The three lines depict the percentage of recurrent Clostridium infection over time based on the number of antecedent non-C. diff antibiotics and 'n' is the number of patients in each category.
In our study, antecedent antibiotic exposure was the only significant RF for recurrent CDI. This supports the widely accepted theory of pathogenesis of CDI, which results from disruption of normal colonic flora which act as a barrier to C. diff. colonization. Stevens et al. 19 showed that cumulative increase in number of antibiotic doses and duration increased the risk of CDI exponentially. Third-and fourth-generation cephalosporins and ciprofloxacin are the most common antibiotics associated with increased risk of recurrent CDI, 6 ,20 and we found a similar trend with exception that penicillins were more commonly used. Hensgens et al. 20 showed that risk of colonization with C. diff was high during and after 3 months of stopping antibiotic therapy.
We did not find an association between recurrent CDI and any transplant-related RF in our cohort. In a nested case-control study by Alonso et al.,
1 acute gastrointestinal GvHD ( ⩾ grade 2, accounting for 55%) was a significant RF for recurrent CDI conferring almost a fivefold increased risk. There are also studies showing a bidirectional relationship between CDI and GvHD, with incidence of GVHD increasing significantly after CDI. Although 31% of allogeneic transplants had ⩾ grade 2 GvHD in our study, we did not see a relationship between GvHD and recurrence of CDI. We stratified severity of GvHD as none to moderate (grade 0-2) and severe (grade 3-4) and still could not find a significant association. Proton pump inhibitor use has been attributed as an RF for recurrent CDI in recent years. 18 We did not find such an association in our analyses. In the study by Willems et al., 3 umbilical cord blood transplantation and TBI used in preparative regimen were identified as RF for CDI in allogeneic transplantation. In contrast, transplant type, source of hematopoietic stem cells, intensity of preparative regimen, number of prior chemotherapy regimens, age or gender were not identified as RFs for recurrent CDI in our study. A study by Hosokawa et al. 21 looking at the relative incidences and outcomes of CDI following unrelated cord blood transplantation and bone marrow transplantation and related PBSC transplantation showed that incidence and prognosis of CDI following unrelated cord blood transplantation were comparable to that of bone marrow transplantation and PBSC transplantation.
Survival analyses revealed a trend for increased mortality among patients with recurrent CDI. A causal role cannot be established without prospective analyses, but it could be due to the emergence of hypervirulent strains of C. diff, such as NAP1 in recent years 22 and severity of the disease. A recent study by Swale et al. 23 revealed that low mannose binding lectin concentrations ( o50 ng/ml), a protein that activates the complement pathway, were associated with threefold increase in CDI recurrence. This suggests that impaired immunity in allogeneic HSCT recipients increases the risk of not only CDI, but also other life-threatening infections and thus the need for prolonged durations of antimicrobial therapy. This suggests the need to consider secondary prophylaxis for CDI in a selected group of allogeneic HSCT recipients with CDI, possibly guided by severity of the infection and duration and number of antecedent non-C. diff antibiotics used. These prophylactic measures could be used in the first 6 months following first CDI as our study shows that most recurrences occur during this time period.
Limitations of our study include a relatively small number of patients with recurrent CDI, which limited the number of variables that can be included in a multivariable model. However, this is the largest RF analysis done so far in allogeneic HSCT recipients. The retrospective nature limited our ability to collect details on the antibiotic doses and duration which would have yielded more valuable information as these patients require prolonged courses of antibiotics for neutropenic fever. In our study, PCR for C. diff toxin detection, which is more sensitive and specific compared with enzyme immunoassay, was used only after 2010. We do not have information on strain typing of C. diff in our study which would be the best way to distinguish relapse from reinfection.
In conclusion, CDI affected 12% of allogeneic HSCT recipients with a recurrence rate of 31% and increased the trend for mortality with recurrence. Antecedent use of antibiotics not targeted against C. diff. was associated with recurrent episodes, with the risk increasing twofold with every increase in the number of antibiotics. Antibiotic use may be a modifiable RF, but given the high rate of systemic and blood-stream infections in allogeneic HSCT recipients, this study could lead us to consider secondary prophylaxis in a select group of patients in the future. Further studies are needed to support the need for secondary prophylaxis of CDI in allogeneic transplant recipients. Prospective studies looking at the number of doses and specific duration of non-C. diff antibiotics associated with recurrent CDI could help in identifying high-risk recipients who would benefit from secondary prophylaxis. Larger studies are needed to ascertain the relationship between GvHD and CDI and their temporal influence on each other.
